Alnylam's RNAi candidate wins orphan designation for hemophilia A

08/20/2013 | American City Business Journals

The FDA granted orphan-drug status to Alnylam Pharmaceuticals' ALN-AT3 as a treatment for hemophilia A, just a week after receiving the same designation for hemophilia B. ALN-AT3, an injectable RNAi therapeutic designed to treat several rare bleeding diseases, is expected to enter Phase I human studies next year.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN